Article
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.
Cancer discovery - 1 Oct 2012
Takezawa Ken, Pirazzoli Valentina, Arcila Maria E, Nebhan Caroline A, Song Xiaoling, de Stanchina Elisa, Ohashi Kadoaki, Janjigian Yelena Y, Spitzler Paula J, Melnick Mary Ann, Riely Greg J, Kris Mark G, Miller Vincent A, Ladanyi Marc, Politi Katerina, Pao William
Abstract excerpt
EGF receptor (EGFR)-mutant lung cancers eventually become resistant to treatment with EGFR tyrosine kinase inhibitors (TKI). The combination of EGFR-TKI afatinib and anti-EGFR antibody cetuximab can overcome acquired resistance in mouse models and human patients. Because afatinib is also a potent HER2 inhibitor, we investigated the role of HER2 in EGFR-mutant tumor cells. We show in vitro and in vivo that...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.